The president threatened to “deploy every tool” in the administration’s arsenal if drug companies don’t cut certain prices by late September.

Although obinutuzumab has not yet received FDA approval in lupus nephritis, findings from a recent survey conducted by ...

U.S. stock futures rose on Thursday after ending on a mixed note on Wednesday. Futures of major benchmark indices were higher ...

World shares retreated Friday after President Donald Trump issued a new set of import duties that will apply to dozens of ...